111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin

EJNMMI Research

Volumn 2, Issue 1, 2012, Pages 1-11

  Cornelissen, Bart ^a   Waller, Andrew ^a   Target, Carol ^a   Kersemans, Veerle ^a   Smart, Sean ^a   Vallis, Katherine A ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Auger electron; F3 peptide; Nucleolin; Nucleolus

Indexed keywords

FLUORESCEIN ISOTHIOCYANATE; INDIUM BENZYL DIETHYLENETRIAMINEPENTAACETIC ACID F3 PEPTIDE IN 111; NUCLEOLIN; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL FRACTIONATION; CELL SURVIVAL; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOUBLE STRANDED DNA BREAK; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG RESPONSE; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RADIATION DOSE DISTRIBUTION; TUMOR XENOGRAFT;

EID: 84875912237     PISSN: None     EISSN: 2191219X     Source Type: Journal    
DOI: 10.1186/2191-219X-2-9     Document Type: Article

References (29)

1. Goldsmith SJ: Radioimmunotherapy of lymphoma: Bexxar and Zevalin. Semin Nucl Med 2010, 40(2):122-135.
2. Adelstein SJ, Merrill C, Sosman Lecture: The Auger process: a therapeutic promise? AJR Am J Roentgenol 1993, 160(4):707-713.
3. Boswell CA, Brechbiel MW: Auger electrons: lethal, low energy, and coming soon to a tumor cell nucleus near you. J Nucl Med 2005, 46(12):1946-1947.
4. Kassis AI: Cancer therapy with Auger electrons: are we almost there? J Nucl Med 2003, 44(9):1479-1481.
5. Kassis AI: The amazing world of auger electrons. Int J Radiat Biol 2004, 80(11-12):789-803.
6. Kassis AI, Adelstein SJ: Radiobiologic principles in radionuclide therapy. J Nucl Med 2005, 46(Suppl 1):4S-12S.
7. Sofou S: Radionuclide carriers for targeting of cancer. Int J Nanomedicine 2008, 3(2):181-199.
8. Cornelissen B, Vallis KA: Targeting the nucleus: an overview of Augerelectron radionuclide therapy. Curr Drug Discov Technol 2010, 7(4):263-279.
9. Christian S, Pilch J, Akerman ME, Porkka K, Laakkonen P, Ruoslahti E: Nucleolin expressed at the cell surface is a marker of endothelial cells in angiogenic blood vessels. J Cell Biol 2003, 163(4):871-878.
10. Porkka K, Laakkonen P, Hoffman JA, Bernasconi M, Ruoslahti E: A fragment of the HMGN2 protein homes to the nuclei of tumor cells and tumor endothelial cells in vivo. Proc Natl Acad Sci USA 2002, 99(11):7444-7449.
11. Zhang Y, Yang M, Park JH, Singelyn J, Ma H, Sailor MJ, Ruoslahti E, Ozkan M, Ozkan C: A surface-charge study on cellular-uptake behavior of F3-peptide-conjugated iron oxide nanoparticles. Small 2009, 5(17):1990-1996.
12. Derfus AM, Chen AA, Min DH, Ruoslahti E, Bhatia SN: Targeted quantum dot conjugates for siRNA delivery. Bioconjug Chem 2007, 18(5):1391-1396.
13. Henke E, Perk J, Vider J, de Candia P, Chin Y, Solit DB, Ponomarev V, Cartegni L, Manova K, Rosen N, Benezra R: Peptide-conjugated antisense oligonucleotides for targeted inhibition of a transcriptional regulator in vivo. Nat Biotechnol 2008, 26(1):91-100.
14. Moody J, Reddy GR, McConville P, Lister RJ, Woolliscroft MJ, Dobrusin EM: In vivo MRI evaluation of targeted nanoparticles in rat 9L brain tumor. Proc Amer Assoc Cancer Res 2006, 47, Abstract #1097.
15. Reddy GR, Bhojani MS, McConville P, Moody J, Moffat BA, Hall DE, Kim G, Koo Y-EL, Woolliscroft MJ, Sugai JV, Johnson TD, Philbert MA, Kopelman R, Rehemtulla A, Ross BD: Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clin Cancer Res 2006, 12(22):6677-6686.
16. Winer I, Wang S, Lee YE, Fan W, Gong Y, Burgos-Ojeda D, Spahlinger G, Kopelman R, Buckanovich RJ: F3-targeted cisplatin-hydrogel nanoparticles as an effective therapeutic that targets both murine and human ovarian tumor endothelial cells in vivo. Cancer Res 2010, 70(21):8674-8683.
17. Bhojani MS, Ranga R, Luker GD, Rehemtulla A, Ross BD, Van Dort ME: Synthesis and investigation of a radioiodinated F3 peptide analog as a SPECT tumor imaging radioligand. PLoS One 2011, 6(7):e22418.
18. Van Dort M, Ross BD, Bhojani MS, Rehemtulla A, Ranga R: Development of a F3 peptide radioligand for SPECT imaging of tumor angiogenesis. Proceedings of the 2009 World Molecular Imaging Conference: September 23-26 2009; Montreal.
19. Drecoll E, Gaertner FC, Miederer M, Blechert B, Vallon M, Muller JM, Alke A, Seidl C, Bruchertseifer F, Morgenstern A, Senekowitsch-Schmidtke R, Essler M: Treatment of peritoneal carcinomatosis by targeted delivery of the radio-labeled tumor homing peptide bi-DTPA-[F3]2 into the nucleus of tumor cells. PLoS One 2009, 4(5):e5715.
20. du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS: Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res 2006, 12(3 Pt 1):904-916.
21. Hnatowich DJ, Layne WW, Childs RL: The preparation and labeling of DTPA-coupled albumin. Int J Appl Radiat Isot 1982, 33(5):327-332.
22. Cornelissen B, Hu M, McLarty K, Costantini D, Reilly RM: Cellular penetration and nuclear importation properties of 111In-labeled and 123I labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells. Nucl Med Biol 2007, 34(1):37-46.
23. Costantini DL, Chan C, Cai Z, Vallis KA, Reilly RM: 111In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer. J Nucl Med 2007, 48(8):1357-1368.
24. Goddu SM, Howell RW, Rao DV: Cellular dosimetry: absorbed fractions for monoenergetic electron and alpha particle sources and S-values for radionuclides uniformly distributed in different cell compartments. J Nucl Med 1994, 35(2):303-316.
25. Nakamura A, Sedelnikova OA, Redon C, Pilch DR, Sinogeeva NI, Shroff R, Lichten M, Bonner WM: Techniques for gamma-H2AX detection. Methods Enzymol 2006, 409:236-250.
26. Edelman MJ, Quam H, Mullins B: Interactions of gemcitabine, carboplatin and paclitaxel in molecularly defined non-small-cell lung cancer cell lines. Cancer Chemother Pharmacol 2001, 48(2):141-144.
27. Boulon S, Westman BJ, Hutten S, Boisvert FM, Lamond AI: The nucleolus under stress. Mol Cell 2010, 40(2):216-227.
28. Moore HM, Bai B, Boisvert FM, Latonen L, Rantanen V, Simpson JC, Pepperkok R, Lamond AI, Laiho M: Quantitative proteomics and dynamic imaging of the nucleolus reveal distinct responses to UV and ionizing radiation. Mol Cell Proteomics 2011, 10(10):M111 009241.
29. Boyd MT, Vlatkovic N, Rubbi CP: The nucleolus directly regulates p53 export and degradation. J Cell Biol 2011, 194(5):689-703.